Provided by Tiger Trade Technology Pte. Ltd.

VanEck Healthcare TruSector ETF

29.19
+0.19710.68%
Post-market: 29.12-0.0725-0.25%16:10 EDT
Volume:399
Turnover:11.60K
Market Cap:583.85K
PE:- -
High:29.19
Open:28.95
Low:28.93
Close:29.00
52wk High:30.68
52wk Low:24.78
Shares:20.00K
Float Shares:20.00K
Volume Ratio:0.50
T/O Rate:2.00%
Dividend:0.21
Dividend Rate:0.74%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Lucid Diagnostics advances Medicare reimbursement and coding infrastructure

TIPRANKS
·
Sep 22

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Sep 22

Viking Therapeutics Surges Nearly 50% Premarket as Once-Every-Two-Week Dosing Retains 97% of Weight Loss

Stock News
·
Sep 22

Viking Therapeutics Stock Surges 36%. it Could Challenge Lilly and Novo's Obesity Empire.

Dow Jones
·
Sep 22

DePuy Synthes Showcases Next-Generation Trauma Innovations at OTA 2026

Reuters
·
Sep 22

J&J DePuy Synthes to Showcase Next-Generation Trauma Devices at Orthopaedic Trauma Association Annual Meeting

Reuters
·
Sep 22

Merck Gets FDA Label Update for WINREVAIR Based on HYPERION Trial

MT Newswires Live
·
Sep 22

Merck says FDA approves update for U.S. product label for Winrevair

TIPRANKS
·
Sep 22

U.S. FDA Approves Update to the Label for Winrevair to Include Data from the Phase 3 Hyperion Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension

Reuters
·
Sep 22

Merck Says Phase 3 Hyperion Trial Shows Winrevair Cuts PAH Clinical Worsening Risk 76%

Reuters
·
Sep 22

AbbVie: EC approves Rinvoq to treat polyarticular juvenile idiopathic arthritis

TIPRANKS
·
Sep 22

AbbVie Announces European Commission Approval of Rinvoq (Upadacitinib)

Reuters
·
Sep 22

AbbVie Says EU Approves Rinvoq for Children with Polyarticular Juvenile Idiopathic Arthritis

Reuters
·
Sep 22

Abbvie Announces European Commission Approval of Rinvoq® (Upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis

THOMSON REUTERS
·
Sep 22

Abbvie - Rinvoq Approved in EU for Pjia in Patients Aged Two Years and Older

THOMSON REUTERS
·
Sep 22